+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Evaluation of induction doses of propofol: comparison between endstage renal disease and normal renal function patients



Evaluation of induction doses of propofol: comparison between endstage renal disease and normal renal function patients



Anaesthesia and Intensive Care 30(5): 584-587



Anaemia, hypoproteinaemia and acidic pH in renal failure patients can alter the pharmacokinetics and pharmacodynamics of anaesthetic agents, resulting in altered dose requirements. We evaluated the induction dose of propofol in adult patients with end-stage renal disease by titrating the hypnotic effect by means of a clinical parameter as well as using a more objective assessment of hypnosis, the Bispectral Index (BIS) monitor. The dose was compared with that for patients with normal renal function. Propofol doses that provided the clinical end-point of hypnosis (syringe drop method), as well as the end-point of a mean (SD) BIS value of 50 (5), were evaluated in 27 end-stage renal disease and 27 normal renal function patients. Propofol was administered at 0.2 mg/kg every 15 seconds until these end-points were achieved. End-stage renal disease patients required significantly higher propofol doses to achieve the clinical end-point of hypnosis (1.42 (0.24) mg/kg versus 0.89 (0.2) mg/kg in normal renalfunction patients, P<0.05 unpaired "t" test). Propofol dose required to achieve a BIS of 50 (5) was also higher in end-stage renal disease patients (2.03 (0.4) mg/kg versus 1.39 (0.43) mg/kg in normal renal function patients, P<0.05). There was a significant negative correlation of propofol dose with preoperative haemoglobin concentration. A hyperdynamic circulation in renal failure patients with anaemia may be responsible for the higher propofol dose requirement in this group.

(PDF emailed within 1 workday: $29.90)

Accession: 046010598

Download citation: RISBibTeXText

PMID: 12413256


Related references

Comparison of pituitary-thyroid function in patients with endstage renal disease and in age- and sex-matched controls. Kidney International 21(2): 362-364, 1982

Pharmacokinetics of cefoperazone 2.0 g and sulbactam 1.0 g coadministered to subjects with normal renal function patients with decreased renal function and patients with end stage renal disease on hemodialysis. Antimicrobial Agents and Chemotherapy 32(4): 503-509, 1988

Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. Anesthesia and Analgesia 95(1): 219-23, Table of Contents, 2002

Loading and maintenance doses of digoxin in patients with normal renal function and those with severely impaired renal function. Journal of Clinical Pharmacology 14(7): 329-338, 1974

Patient-controlled sedation using propofol in eight patients with endstage renal failure. Journal of Anesthesia 18(1): 39-42, 2004

Pharmacodynamic evaluation of timentin and unasyn in patients with endstage renal disease. Pharmacotherapy 12(6): 502-503, 1992

Renal transplantation is well established as the preferred form of replacement therapy for most patients with endstage renal disease. World Journal of Urology 14(4): 205-205, 1996

A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. Journal of Rheumatology 26(12): 2595-2601, 1999

Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease. Journal of Immunology Research 2014: 641962-641962, 2014

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clinical Therapeutics 28(3): 432-444, 2006

The induction of anaesthesia with propofol ('Diprivan') compared in normal and renal failure patients. Postgraduate Medical Journal 61 Suppl 3: 62-63, 1985

Comparison of onset and duration of action of vecuronium in patients with normal renal function and renal failure patients. Anesthesiology (Hagerstown) 79(3A): A358, 1993

Comparison of onset and duration of action of atracurium in patients with normal renal function and with chronic renal failure. Anesthesiology (Hagerstown) 77(3A): A944, 1992